Menu
Not yet recruiting NCT06961682

Effectiveness of MD on MetS Patients

No phase Interventional Obesity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MD.
Who it may be relevant to
Registry conditions: Obesity. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effectiveness of MD on Patient With MetS to Control Hypertension, Diabetes ,Obesity and Dyslipidemia in Patients Attending Assiut University Hospital

Overview

The metabolic syndrome (MetS), is a complicated condition linked to coronary artery disease.This group includes visceral obesity (abdominal or android type obesity), insulin resistance (IR), hypertension, and dyslipidaemia.The global prevalence of MetS is estimated to be about one-quarter of the world population or over a billion global citizens .A high MetS prevalence of 55% was found in Egyptians, 85.6% among diabetics, and 76.6% among hypertensive patients .People can modify their diet, physical activity, decrease smoking habits to lower their chance of developing MetS. Frequent exercise can lower blood pressure while increasing insulin sensitivity, lipolysis, and energy expenditure. It has the ability to improve blood lipid parameters .Diet is one of the most important tools available to improve MetS. However, the diet for the prevention and treatment of MetS remains unspecified beyond weight control and reduction in total calories. Several evidences show that it should generally be low in saturated fats, trans fats, cholesterol, sodium and simple sugars .The adherence to the Mediterranean Diet(MD) brings up two positive features, firstly the activity levels are increased and secondly the environmental impact becomes self-rewarding. The more the MD is favoured, the more the self-productivity is achieved resulting in a stronger life style adaptation .MD causes reduction of CVD incidence and outcomes decreases BP (systolic and diastolic) , inverses association with mortality,improvements in dyslexia, decreases incidence of T2DM.

Interventions

  • Dietary supplement MD
    Red meats and sweets minimal consumption once or twice per month Eggs, cheese, poultry and yoghurt weekly consumption Fish and seafood two to three times per week Olive oil varing amount daily Vegetables and fruits daily consumption Legumes and whole grains (bread, pasta, rice and nuts )daily consumption Measure the effect of Mediterranean diet on patient with MetS to control hypertension, diabetes, obesity and dyslipidemia by measuring blood pressure mmHg regularly, Hba1c before, lipid profile

Primary outcome measures

  • Assessment the effectiveness of MD on obese MetS patients [Time frame: 6 months]
  • Assessment the effectiveness of MD on hypertensive MetS patients [Time frame: 6 months]
  • Assessment the effectiveness of MD on diabetic MetS patients [Time frame: 6 months]
  • Assessment the effectiveness of MD on dyslipidemic MetS patients [Time frame: 6 months]

Eligibility criteria

  • Inclusion criteria:

All people diagnosed as metabolic syndrome

  • (Hypertension(systolic BP≥130 or Diastolic BP ≥85)
  • prediabetes fasting plasma glucose(100-125),oral glucose tolerance test(140-199)Hba1c(5.7-6.4)ADA
  • Diabetes, fasting>125, oral glucose tolerance test>200, Hba1c≥6.5 ADA .
  • Hyperlipidaemia(TG≥150 mg\\dl-HDL<40 in male and <50 in female) \[12\]
  • Obesity(waist circumference ≥102cm in male and ≥88cm in female) \[12\]
  • Exclusion criteria:
  • Type 1 diabetes
  • Patients with renal or advanced liver disease(Failure)
  • Oral contraceptives, psychiatric, neurologic medications and steroid therapy
  • Patients with heart failure and presence of stent
  • Endocrine disease (Thyroid disease especially hypothyroidism-Cushing disease)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06961682 · Fam Med Dep AssiutU

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗